171 related articles for article (PubMed ID: 38228583)
21. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway.
Wei Z; Xia K; Zheng D; Gong C; Guo W
Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
[TBL] [Abstract][Full Text] [Related]
22. Suppression of CLEC3A inhibits osteosarcoma cell proliferation and promotes their chemosensitivity through the AKT1/mTOR/HIF1α signaling pathway.
Ren C; Pan R; Hou L; Wu H; Sun J; Zhang W; Tian X; Chen H
Mol Med Rep; 2020 Apr; 21(4):1739-1748. PubMed ID: 32319617
[TBL] [Abstract][Full Text] [Related]
23. MTHFD1L as a folate cycle enzyme correlates with prognostic outcome and its knockdown impairs cell invasive behaviors in osteosarcoma via mediating the AKT/mTOR pathway.
Wang L; Yang Y; Wang XM; Wang CQ; Zhang YM; Li BL
J Recept Signal Transduct Res; 2020 Dec; 40(6):584-590. PubMed ID: 32456526
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
[TBL] [Abstract][Full Text] [Related]
26. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
27. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
[TBL] [Abstract][Full Text] [Related]
28. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V.
Sun X; Shan HJ; Yin G; Zhang XY; Huang YM; Li HJ
Cell Death Discov; 2022 Feb; 8(1):48. PubMed ID: 35115496
[TBL] [Abstract][Full Text] [Related]
29. Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway.
Pan BL; Tong ZW; Wu L; Pan L; Li JE; Huang YG; Li SD; Du SX; Li XD
Cell Physiol Biochem; 2018; 45(4):1410-1422. PubMed ID: 29462818
[TBL] [Abstract][Full Text] [Related]
30. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth
Ye X; Ruan JW; Huang H; Huang WP; Zhang Y; Zhang F
Aging (Albany NY); 2020 May; 12(10):9489-9499. PubMed ID: 32421688
[TBL] [Abstract][Full Text] [Related]
31. Cirsiliol induces autophagy and mitochondrial apoptosis through the AKT/FOXO1 axis and influences methotrexate resistance in osteosarcoma.
Luo M; Su Z; Gao H; Tan J; Liao R; Yang J; Lin L
J Transl Med; 2023 Dec; 21(1):907. PubMed ID: 38087310
[TBL] [Abstract][Full Text] [Related]
32. Nitazoxanide inhibits osteosarcoma cells growth and metastasis by suppressing AKT/mTOR and Wnt/β-catenin signaling pathways.
Ye C; Wei M; Huang H; Wang Y; Zhang L; Yang C; Huang Y; Luo J
Biol Chem; 2022 Sep; 403(10):929-943. PubMed ID: 35946850
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition.
Yen CC; Hsiao CD; Chen WM; Wen YS; Lin YC; Chang TW; Yao FY; Hung SC; Wang JY; Chiu JH; Wang HW; Lin CH; Chen TH; Chen PC; Liu CL; Tzeng CH; Fletcher JA
Oncotarget; 2014 Feb; 5(3):716-25. PubMed ID: 24566468
[TBL] [Abstract][Full Text] [Related]
35. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
36. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
37. Licochalcone B Induced Apoptosis and Autophagy in Osteosarcoma Tumor Cells via the Inactivation of PI3K/AKT/mTOR Pathway.
Huang Z; Jin G
Biol Pharm Bull; 2022 Jun; 45(6):730-737. PubMed ID: 35431285
[TBL] [Abstract][Full Text] [Related]
38. The requirement of the mitochondrial protein NDUFS8 for angiogenesis.
Xiong QW; Jiang K; Shen XW; Ma ZR; Yan XM; Xia H; Cao X
Cell Death Dis; 2024 Apr; 15(4):253. PubMed ID: 38594244
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
40. LRIG2 regulates cell proliferation, migration and apoptosis of osteosarcoma.
Li ZQ; Liao WJ; Sun BL; Luo ZW; Zhong NS; Wu JB; Liu ZL; Liu JM
BMC Cancer; 2022 Oct; 22(1):1029. PubMed ID: 36183058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
